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Abstract
Background: Clinical differentiation of influenza from dengue and other febrile illnesses (OFI) is difficult, and
available rapid diagnostic tests have limited sensitivity.
Methods: We conducted a retrospective study to compare clinical and laboratory findings between (i) influenza
and dengue and (ii) influenza and OFI.
Results: Of 849 enrolled patients, the mean time between illness onset and hospital presentation was 1.7, 3.7,
and 3 days for influenza, dengue, and OFI, respectively. Among pediatric patients (≤18 years) (445 influenza,
24 dengue, and 130 OFI), we identified absence of rashes, no leukopenia, and no marked thrombocytopenia
(platelet counts <100 × 109 cells/L) as predictors to distinguish influenza from dengue, whereas rhinorrhea, malaise,
sore throat, and mild thrombocytopenia (platelet counts 100–149 × 109/L) were predictors that differentiated
influenza from OFI. Among adults (>18 years) (81 influenza, 124 dengue, and 45 OFI), no leukopenia and no marked
thrombocytopenia distinguished influenza from dengue, while rhinorrhea and malaise differentiated influenza from
OFI. A diagnostic algorithm developed to distinguish influenza from dengue using rash, leukopenia, and marked
thrombocytopenia showed >90% sensitivity to identify influenza in pediatric patients.
Conclusions: This study identified simple clinical and laboratory parameters that can assist clinicians to distinguish
influenza from dengue and OFI. These findings may help clinicians diagnose influenza and facilitate appropriate
management of affected patients, particularly in resource-poor settings.
Keywords: Influenza, Dengue, Other febrile illnesses
Background
Influenza is one of the most common infectious diseases
worldwide [1]. The spectrum of clinical manifestations
ranges from mild–form nonspecific febrile illness, such
as cough, sore throat, headache, rhinorrhea, malaise, and
muscle ache, to respiratory failure and death [2-4]. Its
symptoms and signs can be similar to other viral ill-
nesses such as dengue, making the infections difficult to
distinguish. The clinical manifestations of dengue illness
vary greatly, ranging from a mild, flu-like, and self-
limited febrile illness to severe dengue [5,6]. Influenza
and dengue overlap geographically in tropical and sub-
tropical regions of the world [1,7]. Concurrent influenza
and dengue outbreaks have been reported [8-11]. The
overlapping clinical features of influenza and dengue cre-
ated clinical diagnosis and management challenges during
simultaneous influenza and dengue outbreaks in Puerto
Rico in 1977 [11]. Dengue epidemics have occurred in
Taiwan for decades [12,13]. An outbreak of 2009 pandemic
H1N1 occurred in Taiwan after the first case was identified
on May 20, 2009 [14]. The overlapping symptoms and
signs of influenza and dengue created a confusing clinical
situation and challenges in etiology identification. Although
rapid diagnostic tests can help confirm an influenza diag-
nosis, their sensitivity ranges from 40–70% depending
on the day of illness and specimen type [15]. Definitive
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diagnosis of dengue is made using serology tests, but these
tests are not always readily available in most clinical labora-
tories [7,16]. Our study aimed to identify clinical and la-
boratory features that distinguish influenza from dengue
and other febrile illnesses (OFI) in dengue and non-dengue
endemic settings. We applied decision tree analysis to our
dataset to discriminate patients with influenza from those
with dengue. Our findings may be valuable for clinicians
working in crowded emergency rooms (ER) in countries
with limited medical resources.
Methods
Ethics statement
The study was approved by the Institutional Review Board
of Kaohsiung Chang Gung Memorial Hospital (KSCGMH)
(Document no. 102-4695B). Informed consent was not
required as the data were analyzed anonymously.
Study population, diagnosis and definition
We conducted a retrospective study of 849 febrile pa-
tients (ear temperature ≥38°C) who presented during
2008 and 2010 with possible dengue and influenza infec-
tions to the ER at KSCGMH, a 2,600-bed primary care
and tertiary referral medical center in southern Taiwan.
All patient medical records were reviewed, and clinical
and laboratory data at the time of hospital presentation
were extracted for analysis.
Patients with influenza infections were defined as those
laboratory-positive for influenza with influenza-like illness.
Influenza-like illness was defined according to World
Health Organization (WHO) guidelines: fever, cough, or
sore throat [17]. Laboratory diagnosis of influenza was
made for patient’s respiratory specimens (nasopharyngeal
or pharyngeal swabs) positive for virus-specific ribonucleic
acid by real-time reverse transcriptase-polymerase chain
reaction (RT-PCR) (TAIGEN Bioscience Corporation,
Taiwan) [18]. All PCRs were performed at the central test-
ing laboratory of KSCGMH using the standard real-time
RT-PCR influenza procedure described by the Centers for
Disease Control and Prevention [19].
All dengue cases included in this study were con-
firmed by at least one of the following criteria: (i) posi-
tive dengue virus-specific real-time RT-PCR (QuantiTect
SYBR Green RT-PCR kit; Qiagen, Hilden, Germany)
[20], (ii) positive dengue virus-specific immunoglobulin
(Ig) M antibody enzyme-linked immunosorbent assay
of acute-phase serum, after excluding cross-reactions to
Japanese encephalitis virus [21], (iii) a fourfold increase
in dengue virus-specific IgG antibody in convalescent
serum compared to the acute phase, and (iv) acute-
phase serum positive for dengue virus-specific nonstruc-
tural glycoprotein-1 (NS1) antigen (Bio-Rad Laboratories,
Marnes-la-Coquette, France) [22,23]. Dengue diagnostic
tests were performed by the Centers for Disease Control
and Prevention in Taiwan. Dengue patients in this study
were classified as dengue fever without warning signs, den-
gue fever with warning signs and severe dengue based on
2009 WHO case definitions [7]. Patients who did not meet
the laboratory diagnosis criteria for influenza and dengue
were classified as OFI in our analyses.
Leukopenia was defined as a peripheral white cell
count <3.0 × 109 cells/L (reference value, 3.0–10.5 × 109
cells/L), mild thrombocytopenia as a peripheral platelet
count of 149–100 × 109 cells/L, and marked throm-
bocytopenia as a peripheral platelet count <100 × 109
cells/L. Acute hepatitis referred to serum alanine amino-
transferase (ALT) levels greater than 1,000 U/L (reference
value, <40 U/L).
Statistical analysis
Patients were categorized as having (i) influenza, (ii) den-
gue, or (iii) OFI. To distinguish influenza from dengue or
OFI in a dengue and non-dengue endemic settings, univar-
iate analyses were performed to compare clinical and la-
boratory characteristics between (i) influenza and dengue,
and (ii) influenza and OFI. Categorical variables were
compared using Chi-square or Fisher exact tests, and con-
tinuous variables were compared using Student’s t or
Mann-Whitney U tests. A 2-tailed P <0.05 was considered
statistically significant. Significant variables in the univari-
ate analyses were entered into a multivariate logistic re-
gression model to determine independent predictor(s) of
(i) influenza versus dengue, and (ii) influenza versus OFI.
The sensitivity and specificity of each significant variable
was assessed. Classification and regression tree analysis
was performed [24]. The variables found to be significant
in multivariate logistic regression with sensitivity greater
than 80% were used to establish diagnostic decision trees
to distinguish between patients with influenza and those
with dengue [24]. Diagnosis was achieved by stepwise bin-
ary splitting, where one variable was entered at each node
and, depending on the answer, a branch of the tree con-
taining another variable was followed. Splitting stopped at
nodes with a minimum classification of dengue, maximum
classification of influenza, or a small number of patients in
the node. For each terminal node, patients were classified
as having low or high probability for influenza infection.
To investigate the impact of age on the clinical presenta-
tion of influenza, dengue, and OFI, stratified analyses were
performed for pediatric (≤18 years) and adult (>18 years)
patients to examine the differences in clinical and labora-
tory characteristics between (i) influenza and dengue, and
(ii) influenza and OFI.
Results
Demographic and clinical features of the patients
Of 849 patients, 526 (315 men and 211 women; mean
age, 13.6 ± 13.5 years) were diagnosed with influenza,
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148 (83 men and 65 women; mean age, 45.1 ± 4.5 years)
with dengue, and 175 (106 men and 69 women; mean
age, 15.3 ± 15.9 years) with OFI. None of the patients
had concurrent influenza and dengue infections. Demo-
graphic, clinical, and laboratory information are summa-
rized in Tables 1 and 2.
Of 526 (445 [84.6%] patients aged ≤18 years) influenza
infections, 447 (85%) were 2009 pandemic H1N1 and 79
(15%) were seasonal H3N2. The mean interval between
onset of illness and the patient’s arrival at the ER
was 1.7 ± 1.2 days, and the mean fever duration was
2.8 ± 1.6 days. Besides fever, the 3 most common symp-
toms were cough (67.6%), rhinorrhea (63.3%), and sore
throat (39.3%). Mild thrombocytopenia was detected in
38 (15.9%) of the 238 patients with an available periph-
eral platelet count. Of 364 patients receiving oseltamivir,
107 (29.4%) started therapy >48 h after illness onset. The
3 most common influenza-associated complications were
pneumonia (5.1%), meningoencephalitis (1.1%), and acute
respiratory distress syndrome (ARDS) (0.9%) (Table 3).
The mortality rate was 0.9%, comprised of 5 patients
(2 pandemic 2009 H1N1 and 3 seasonal H3N2; 4 women
and 1 man, median age of 24 years [range 2–72 years]). All
fatal cases received oseltamivir therapy >48 h after illness
onset. Pneumonia was detected in all 5 fatal cases, ARDS
and meningoencephalitis each in 3 (60% each), intracranial
hemorrhage in 2 (40%), and myocarditis and gastrointes-
tinal bleeding each in 1 (20% each).
Among 148 patients diagnosed with dengue infection
(24 [16.2%] patients aged ≤18 years), 64 (43.2%) were
dengue fever without warning signs, 77 (52%) were den-
gue fever with warning signs, and 7 (4.7%) were severe
dengue, based on 2009 WHO case definitions [7]. An
individual patient might have received more than one
Table 1 Demographics, clinical features, and outcomes of patients with influenza, dengue, and other febrile illnesses
Variable Influenza (n = 526) Dengue (n = 148) Other febrile illnesses (n = 175) Pa Pb
Mean age (± SD), years 13.6 ± 13.5 45.1 ± 4.5 15.3 ± 15.9 <0.001 0.941
Age group (n, [%])
≤ 18 years 445 (84.6) 24 (16.2) 130 (74.3) - -
>18 years 81 (15.4) 124 (83.8) 45 (25.7) - -
Male gender (n, [%]) 315 (59.9) 83 (56.1) 106 (60.6) 0.406 0.873
Underlying conditionc (n, [%])
Bronchial asthma 14 (26.7) 0 5 (2.9) - -
Diabetes mellitus 10 (1.9) 17 (11.5) 2 (1.1) - -
Hypertension 15 (2.8) 30 (20.3) 2 (1.1) - -
Influenza A virus subtype (n, [%])
Pandemic 2009 H1N1 447 (85) - - - -
Seasonal H3N2 79 (15) - - - -
Dengue disease severity (n, [%])
Dengue without warning signs - 64 (43.2) - - -
Dengue with warning signs - 77 (52) - - -
Severe dengue - 7 (4.7) - - -
Dengue virus serotypes (n/N, [%])
Serotype I - 10/40 (25) - - -
Serotype II - 17/40 (42.5) - - -
Serotype III - 12/40 (30) - - -
Serotype IV - 1/40 (2.5) - - -
Mean interval from onset of symptoms to emergency
room presentation, days (± SD)
1.7 ± 1.2 3.7 ± 1.8 3.0 ± 2.1 - -
Mean fever duration, days (± SD) 2.8 ± 1.6 4.0 ± 2.3 ND <0.001 -
Use of oseltamivir >48 h (n/N, [%]) 107/364 (29.4) - - - -
Fatalities (n, [%]) 5 (0.9) 0 0 0.234 0.196
n/N = number of patients/total number of patients with data available; ND = no data.
aInfluenza vs. dengue.
bInfluenza vs. other febrile illnesses.
cAn individual patient might have more than one underlying disease/condition.
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dengue diagnostic test. Of laboratory-positive dengue
cases, 40 were confirmed by RT-PCR, 71 by IgM of
acute phase serum, 47 by fourfold increase in IgG titer
in paired acute and convalescent serum, and 78 by de-
tection of NS1 antigen. Of 71 patients positive for IgM
antibody, a fourfold rise in IgG titer in paired serum was
found in 31 patients, detection of NS1 antigen in 29,
positive RT-PCR and NS1 antigen in 6, fourfold increase
in IgG titer in paired serum and positive NS1 antigen in
3, and fourfold rise in IgG titer in paired serum and
positive RT-PCR in 2. The mean time lapse from onset
of symptoms to ER presentation was 3.7 ± 1.8 days, and
the mean fever duration was 4.0 ± 2.3 days. The 3 most
common symptoms other than fever in dengue patients
were malaise (64.2%), rashes (59.5%), and joint pain
(50%). Marked thrombocytopenia and leukopenia were
found in 109 (74.6%) and 82 (56%) patients, respectively,
of 146 patients with complete blood counts. Forty pa-
tients had available RT-PCR data; of these, dengue virus
serotype II was detected in 17 (42.5%) patients, serotype
III in 12 (30%), serotype I in 10 (25%), and serotype IV
in 1 (2.5%). Of 148 dengue patients, 14 (9.5%) experienced
gastrointestinal bleeding (Table 3). All dengue patients
recovered.
Table 4 describes the diagnosis of the 175 patients
with OFI (130 [74.3%] patients aged ≤18 years). The
3 leading etiologies of OFI were acute pharyngitis
(38.8%), acute bronchitis (25.7%), and bronchopneu-
monia (16%). The mean interval from onset of illness
to ER presentation was 3.0 ± 2.1 days. All patients with
OFI recovered.
Table 2 Symptoms/signs and laboratory characteristics of patients with influenza, dengue, and other febrile illnesses
Variable Influenza (n = 526) Dengue (n = 148) Other febrile illnesses (n = 175) Pa Pb
Symptom/signc (n [%])
Rhinorrhea 333 (63.3) 0 73 (41.7) <0.001 <0.001
Cough 356 (67.6) 38 (25.7) 112 (64) <0.001 0.396
Sore throat 207 (39.3) 24 (16.2) 43 (24.6) <0.001 <0.001
Malaise 183 (34.8) 95 (64.2) 21 (12) <0.001 <0.001
Headache 149 (28.3) 62 (41.9) 33 (18.9) 0.001 0.015
Vomiting/nausea 116 (22.1) 43 (29.1) 37 (21.1) 0.076 0.801
Diarrhea 57 (10.8) 15 (10.1) 26 (14.9) 0.807 0.154
Abdominal pain 40 (7.6) 31 (20.9) 18 (10.3) <0.001 0.265
Joint pain 26 (4.9) 74 (50) 10 (5.7) <0.001 0.539
Orbital pain 0 17 (11.5) 2 (1.1) <0.001 0.062
Rashes 5 (0.9) 88 (59.5) 0 <0.001 0.196
Dyspnea 41 (7.8) 3 (2) 1 (0.6) 0.008 <0.001
Drowsiness 13 (2.5) 0 0 0.083 0.036
Seizures 8 (1.5) 0 0 0.211 0.211
Laboratory characteristics
Leukopenia (WBC <3.0 × 109 cells/L) (n/N [%]) 9/283 (3.2) 82/146 (56) 4/152 (2.6) <0.001 0.749
Platelet count 149–100 × 109 cells/L (n/N [%]) 38/238 (15.9) 27/146 (18.5) 5/133 (3.7) 0.522 0.003
Platelet count <100 × 109 cells/L (n/N [%]) 7/238 (2.9) 109/146 (74.6) 3/133 (2.3) <0.001 0.696
WBC =white blood cell count; n/N = number of patients/total number of patients with data available.
aInfluenza vs. dengue.
bInfluenza vs. other febrile illnesses.
cAn individual patient might have more than one symptom/sign.






Pneumonia 27b (5.1) 1 (0.6) 0.016
ARDS 5c (0.9) 0 0.234
Meningoencephalitis 6d (1.1) 0 0.192
Intracranial bleeding 2d (0.4) 0 0.452
Gastrointestinal bleeding 2d (0.4) 14 (9.5) <0.001
Myocarditis 1d (0.2) 0 0.596
Acute hepatitis (ALT >1,000 U/L) 2d (0.4) 0 0.452
Data are number (%) of patients. ARDS = acute respiratory distress syndrome;
ALT = alanine aminotransferase.
aAn individual patient might have more than one complication.
bOf 27 influenza patients with pneumonia, 15 cases were 2009 pandemic
H1N1 and 12 cases were H3N2.
cOf 5 influenza patients with ARDS, 4 cases were 2009 pandemic H1N1 and 1
case was H3N2.
dPatient(s) with 2009 pandemic H1N1 infection.
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Clinical and laboratory characteristics distinguishing
influenza from dengue
Comparisons between patients with influenza (n = 526)
and dengue (n =148) are shown in Tables 1, 2, 3, 5, and
6. Patients with influenza were significantly younger, had
shorter fever duration, and presented at the ER earlier
than patients with dengue (Table 1). Rhinorrhea, cough,
sore throat, and dyspnea were reported significantly
more frequently in patients with influenza than those
with dengue (Table 2). Significantly lower frequencies
of malaise, headache, abdominal pain, joint pain, or-
bital pain, and rashes were noted in patients with in-
fluenza than in those with dengue (Table 2). Dengue
patients had significantly higher incidences of leukopenia,
marked thrombocytopenia, and gastrointestinal bleeding in
addition to lower incidence of pneumonia (Tables 2 and 3).
Multivariate analysis disclosed absence of rashes (odds ra-
tio [OR], 131.336), no leukopenia (OR, 24.978), and no
marked thrombocytopenia (OR, 105.973) as predictive fac-
tors that distinguished influenza from dengue (Table 6).
The sensitivities of absence of rashes, without leukopenia,
and no marked thrombocytopenia were 98.3%, 96.9%, and
97.9%, while the specificities were 60%, 55.9%, and 74.5%,
respectively.
Symptoms and laboratory characteristics of influenza
infection varied by patient age (Table 5). Pediatric influ-
enza patients (≤18 years, n = 445) had significantly higher
frequencies of rhinorrhea and cough; lower frequencies of
malaise, orbital pain and rashes; and lower incidences of
leukopenia and marked thrombocytopenia compared with
dengue patients (n = 24) (Table 5). Multivariate analysis
showed absence of rashes (OR, 326.393), no leukopenia
(OR, 122.116) and no marked thrombocytopenia (OR,
88.632) to be independent predictors for distinguishing
influenza from dengue in pediatric patients (Table 6).
For individuals >18 years of age, patients with influenza
(n = 81) had greater occurrence of rhinorrhea, cough,
sore throat, and dyspnea; they also presented with lower
frequencies of nausea and vomiting, abdominal pain, joint
pain, orbital pain, and rashes as well as lower incidences of
leukopenia and marked thrombocytopenia (Table 5) com-
pared to patients with dengue (n = 124). Multivariate ana-
lysis indicated that no leukopenia (OR, 13.99) and no
marked thrombocytopenia (OR, 34.096) distinguished in-
fluenza from dengue in adults (Table 6).
Clinical and laboratory characteristics distinguishing
influenza from OFI
Comparisons between patients with influenza (n = 526)
and OFI (n = 175) are summarized in Tables 1, 2, 5, and
6. Significant differences in clinical and laboratory fea-
tures between influenza and OFI included the presence
of rhinorrhea, sore throat, malaise, headache, dyspnea,
drowsiness, and mild thrombocytopenia (Table 2). Multi-
variate analysis revealed that rhinorrhea (OR, 3.350),
malaise (OR, 6.050), sore throat (OR, 3.407), dyspnea
(OR, 47.335), and mild thrombocytopenia (OR, 3.779)
were independent predictive factors that distinguished
influenza from OFI (Table 6). The sensitivities of rhi-
norrhea, malaise, sore throat, dyspnea, and mild throm-
bocytopenia were 63.9%, 44.1%, 44.1%, 17.3%, and 15.9%,
respectively.
As shown in Tables 5 and 6, significantly higher pro-
portions of pediatric patients with influenza (n = 445)
experienced rhinorrhea, sore throat, malaise, headache,
dyspnea, and mild thrombocytopenia compared with
OFI (n = 130); multivariate analysis showed rhinorrhea
(OR, 2.765), malaise (OR, 11.129), sore throat (OR, 3.575),
dyspnea (OR, 20.867), and mild thrombocytopenia (OR,
7.138) to be independent predictive factors that differenti-
ated influenza from OFI in pediatric patients. Compared to
adults with OFI (n = 45), adult patients with influenza
(n = 81) had significantly higher frequencies of rhinorrhea,
cough, malaise, diarrhea, and dyspnea; multivariate analysis
revealed rhinorrhea (OR, 4.726) and malaise (OR, 3.108) to
be predictive factors that distinguished influenza from OFI
in adults.
Classification tree distinguishing influenza from dengue
Variables found to be significant in multivariate logistic
regression were used to establish classification and re-
gression trees. As shown in Figure 1, the initial splitting
variable in the tree is a rash, followed by leukopenia and
marked thrombocytopenia to distinguish influenza from
dengue. The three nodes with low probability of influ-
enza infection in pediatric patients were (i) presence of
rashes, (ii) absence of rashes but with leukopenia and
(iii) absence of rashes, without leukopenia, but with
marked thrombocytopenia. There was a high probability
of influenza infection among pediatric patients without
rashes, no leukopenia and with no marked throm-
bocytopenia (94.2% of patients with influenza). Among
adult patients, high probability of influenza was associated
Table 4 Etiologies of 175 patients with other febrile
illnesses
Variable
Acute pharyngitis 68 (38.8)
Acute bronchitis 45 (25.7)
Bronchopneumonia 28 (16)





Data are number (%) of patients.
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with no leukopenia and no marked thrombocytopenia
(87.8% of patients with influenza) (Figure 2).
Discussion
Our study investigated simple clinical and laboratory
features to identify patients with influenza among chil-
dren and adults with acute febrile illness in ER in den-
gue and non-dengue endemic areas. In our series, the
mean time lapse between onset of illness and ER presen-
tation was 1.7, 3.7, and 3 days for influenza, dengue, and
OFI, respectively. This permits a detailed comparison of
early clinical and laboratory characteristics between in-
fluenza and dengue or OFI.
The symptoms of influenza overlap substantially with
dengue and OFI (Table 2). We found that symptoms
resulting from respiratory tract infections such as cough,
rhinorrhea, sore throat, and dyspnea were more preva-
lent in patients with influenza than with dengue. In con-
trast, non-respiratory tract symptoms including rashes,
headache, abdominal pain, joint pain, and orbital pain were
less common in the patients with influenza compared to
patients with dengue. The influenza virus primarily infects
epithelial cells of the respiratory tract and causes upper re-
spiratory symptoms [25]. Damage to infected cells results
in release of inflammatory mediators, leading to a systemic
response (i.e., fever, headache, joint pain, malaise, and
myalgia) with symptoms similar to other viral illnesses
such as dengue [26,27].
The overlapping geographic range of influenza and
dengue as well as simultaneous dengue and influenza
outbreaks [8-11], often in resource-limited countries,
leads to diagnostic difficulties, as nonspecific symptoms
are common to both infections. Early detection of influ-
enza and dengue is especially important because influ-
enza may be prevented through proper isolation and
treated using antiviral agents [28,29], whereas failure to
make a timely dengue diagnosis with adequate fluid re-
placement can lead to severe dengue [30]. Our study
demonstrated that the presence of leukopenia (white cell
count <3.0 × 109 cells/L) and marked thrombocytopenia
(platelet count <100 × 109 cells/L) are useful for differen-
tiating dengue from influenza in both adults and pediatric
Table 5 Age-specific symptoms/signs and laboratory features of patients with influenza, dengue, and other
febrile illnesses
Variable Age ≤18 years Age >18 years
Inf vs. Den (Inf, n = 445;
Den, n = 24)
Inf vs. OFI (Inf, n = 445;
OFI, n = 130)
Inf vs. Den (Inf, n = 81;
Den, n = 124)
Inf vs. OFI (Inf, n = 81;
OFI, n = 45)
Symptom/signa (n [%])
Rhinorrhea 297 (66.7) vs. 0*** 297 (66.7) vs. 65 (50)** 36 (44.4) vs. 0*** 36 (44.4) vs. 8 (17.8)**
Cough 311 (69.9) vs. 3 (12.5)*** 311 (69.9) vs. 94 (72.3) 45 (55.6) vs. 35 (28.2)*** 45 (55.6) vs. 18 (40)*
Sore throat 163 (36.6) vs. 4 (16.7) 163 (36.6) vs. 27 (20.8)** 44 (54.3) vs. 20 (16.1)*** 44 (54.3) vs. 16 (35.6)
Malaise 141 (31.6) vs. 14 (58.3)* 141 (31.6) vs. 8 (6.2)*** 42 (51.9) vs. 81 (65.3) 42 (51.9) vs. 13 (28.9)*
Headache 125 (28.1) vs. 11 (45.8) 125 (28.1) vs. 21 (16.2)** 24 (29.6) vs. 51 (41.1) 24 (29.6) vs. 12 (26.7)
Vomiting/nausea 106 (23.8) vs. 8 (33.3) 106 (23.8) vs. 33 (25.4) 10 (12.3) vs. 35 (28.2)** 10 (12.3) vs. 4 (8.9)
Diarrhea 54 (12.1) vs. 3 (12.5) 54 (12.1) vs. 19 (14.6) 3 (3.7) vs. 12 (9.7) 3 (3.7) vs. 7 (15.6)*
Abdominal pain 34 (7.6) vs. 4 (16.7) 34 (7.6) vs. 14 (10.8) 6 (7.4) vs. 27 (21.8)** 6 (7.4) vs. 4 (8.9)
Joint pain 18 (4) vs. 6 (25) 18 (4) vs. 7 (5.4) 8 (9.9) vs. 68 (54.8)*** 8 (9.9) vs. 3 (6.7)
Orbital pain 0 vs. 2 (8.3)** 0 (0) vs. 2 (1.5) 0 vs. 15 (12.1)** 0 vs. 0
Rashes 5 (1.1) vs. 11(45.8)*** 5 (1.1) vs. 0 0 vs. 77 (62.1)*** 0 vs. 0
Dyspnea 24 (5.6) vs. 1 (4.1) 24 (5.6) vs. 1 (0.8)* 17 (3.7) vs. 2 (1.6)*** 17 (3.7) vs. 0**
Drowsiness 10 (2.2) vs. 0 10 (2.2) vs. 0 3 (3.7) vs. 0 3 (3.7) vs. 0
Seizures 6 (1.3) vs. 0 6 (1.3) vs. 0 2 (2.5) vs. 0 2 (2.5) vs. 0
Laboratory characteristics
Leukopenia (WBC <3.0 × 109 cells/L)
(n/N [%])
6/231 (2.6) vs. 14/23 (60.8)*** 6/231 (2.6) vs. 1/116 (0.8) 3/52 (5.8) vs. 68/123 (55.3)*** 3/52 (5.8) vs. 3/36 (8.3)
Platelet count 149–100 × 109 cells/L
(n/N [%])
24/189 (12.6) vs. 6/23 (26) 24/189 (12.6) vs. 2/106 (1.9)** 14/49 (28.6) vs. 21/123 (17.1) 14/49 (28.6) vs. 3/27 (11.1)
Platelet count <100 × 109 cells/L
(n/N [%])
3/189 (1.6) vs. 12/23 (52.2)*** 3/189 (1.6) vs. 2/106 (1.9) 4/49 (8.2) vs. 97/123 (78.9)*** 4/49 (8.2) vs. 1/27 (3.7)
Inf = influenza; Den = dengue; OFI = other febrile illnesses; WBC = white blood count; n/N = number of patients/total number of patients with data available.
*P < 0.05; **P < 0.01; ***P < 0.001.
aAn individual patient might have more than one symptom/sign.
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patients. The absence of rash further discriminated influ-
enza from dengue in pediatric patients. Rash associated
with influenza is not a common manifestation, occurring
in only 2-8% of patients, usually children [31,32]. In
contrast, the reported frequency of rash in dengue
cases ranges from 46–68%, particularly in children less
than 15 years who usually have a nonspecific febrile syn-
drome accompanied by rash [33,34]. Mild leukopenia and
relative lymphopenia are typical findings of influenza;
thrombocytopenia may be present in complicated cases
[4,14,25]. Notably, our study and others found leukopenia
and thrombocytopenia to be common laboratory findings
in dengue infection, with platelet counts below 20 × 109
per liter often observed in severe dengue [7,30]. A study
examining predictors of diagnosis in 1,962 febrile travelers
returning from the tropics found the main predictors of
dengue infection compared with other fevers, excluding
malaria, to include skin rash, thrombocytopenia, and
leukopenia [35]. This finding was consistent with our
study findings.
Our data suggest that skin rash, leukopenia (white cell
count <3.0 × 109 cells/L), and platelet counts <100 × 109
cells/L were useful to predict negative influenza results
during influenza and dengue epidemics. However, it is
Table 6 Sensitivity, specificity, and multivariate logistic regression for prediction of influenza versus dengue and









95% CI P Sensitivity% Specificity%
Influenza vs. dengue
All ages
No skin rashes 234/238 (98.3) 58/145 (40) - 131.336 35.416-487.039 <0.001 98.3 60
No leukopeniaa 225/232 (96.9) 64/145 (44.1) - 24.978 7.010-89.006 <0.001 96.9 55.9
No marked thrombocytopeniab 233/238 (97.9) 37/145 (25.5) - 105.973 31.687-354.419 <0.001 97.9 74.5
Age ≤18 years
No skin rashes 185/189 (97.9) 12/23 (52.2) - 326.393 30.860-3452.098 <0.001 97.9 52.2
No leukopeniaa 185/189 (97.9) 9/23 (39.1) - 122.116 10.888-1369.665 <0.001 97.9 60.9
No marked thrombocytopeniab 186/189 (98.4) 11/23 (47.8) - 88.632 6.443-1219.174 0.001 98.4 52.2
Age >18 years
No leukopeniaa 46/49 (93.9) 55/122 (45.1) - 13.99 3.628-53.946 <0.001 93.9 54.9
No marked thrombocytopeniab 45/49 (91.8) 26/122 (21.3) - 34.096 10.622-109.445 <0.001 91.8 78.7
Influenza vs. other febrile
illnesses
All ages
Rhinorrhea 152/238 (63.9) - 57/137 (41.6) 3.350 1.997-5.618 <0.001 63.9 58.4
Malaise 105/238 (44.1) - 16/137 (11.7) 6.050 3.207-11.414 <0.001 44.1 88.3
Sore throat 105/238 (44.1) - 30/137 (21.9) 3.407 1.960-5.922 <0.001 44.1 78.1
Dyspnea 41/238 (17.3) - 1/137 (0.7) 47.335 6.174-632.919 <0.001 17.3 99.3
Mild thrombocytopeniac 38/238 (15.9) - 5/137 (3.6) 3.779 1.309-10.908 0.014 15.9 96.4
Age ≤18 years
Rhinorrhea 131/189 (69.3) - 53/106 (50) 2.765 1.531-4.997 0.001 69.3 50
Malaise 76/189 (40.2) - 6/106 (5.7) 11.129 4.455-27.802 <0.001 40.2 94.3
Sore throat 83/189 (43.9) - 21/106 (19.8) 3.575 1.892-6.753 <0.001 43.9 80.2
Dyspnea 24/189 (12.7) - 1/106 (0.9) 20.867 2.641-164.872 0.004 12.7 99
Mild thrombocytopeniac 24/189 (12.7) - 2/106 (1.9) 7.138 1.509-33.769 0.013 12.7 98.1
Age >18 years -
Rhinorrhea 36/81 (44.4) - 8/45 (17.8) 4.726 1.654-13.5 0.004 44.4 82.2
Malaise 42/81 (51.9) - 13/45 (28.9) 3.108 1.224-7.897 0.017 51.9 71.1
n/N = number of patients/total number of patients with data available; CI = confidence interval.
aLeukopenia is defined as white cell counts <3.0 × 109 cells/L.
bMarked thrombocytopenia is defined as platelet counts <100 × 109 cells/L.
cMild thrombocytopenia is defined as platelet counts 149-100 × 109 cells/L.
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unlikely that any single indicator will be useful in clinical
practice because these symptoms and laboratory findings
can be present in both infections [11]. In our series, we
developed two simple and practical diagnostic algo-
rithms using clinical and laboratory indicators to distin-
guish influenza from dengue in adult and pediatric
patients, respectively. We found that the diagnostic algo-
rithm correctly classified 94.2% of pediatric patients with
influenza in the “high probability” group with only one
misclassified dengue patient (Figure 1). Analysis of our
data after excluding pediatric patients showed similar re-
sults, except that skin rash that was no longer associated
with influenza infection in adult patients; however, the
diagnostic tree (Figure 2) still correctly classified 87.8%
of adult influenza cases as “high probability”. These find-
ings underscored that rash, leukopenia, and marked
thrombocytopenia could help to establish a diagnostic
algorithm to distinguish influenza from dengue patients
during outbreaks of both diseases. Additional prospect-
ive studies are needed to validate this predictive model
in other dengue-endemic regions and in populations
with different ethnicities.
The wide range of influenza-associated symptoms
often makes it difficult to distinguish from other febrile
Figure 1 Diagnostic algorithm to discriminate between influenza and dengue in pediatric patients. Terminal nodes are marked as “low
probability” or “high probability” for influenza infection.
Figure 2 Diagnostic algorithm to discriminate between influenza and dengue in adult patients. Terminal nodes are marked as “low
probability” or “high probability” for influenza infection.
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or respiratory illnesses [25]. A crowded ER can make it
challenging for physicians to differentiate between influ-
enza and OFI [36]. Early antiviral treatment (≤48 h) of
influenza is especially important for patients with under-
lying risk factors to avoid otherwise preventable morbid-
ity and mortality [37]. Our results demonstrate that
rhinorrhea, malaise, sore throat, and dyspnea in addition
to a slightly low platelet count (100–149 × 109 cells/L) in
children, as well as rhinorrhea and malaise in adults
were valuable predictors during the evaluation of the
likelihood of influenza versus OFI in a non-dengue en-
demic setting. However, apart from rhinorrhea, which
lacked adequate sensitivity and specificity, we found that
all other variables were specific (>70%) but not sensitive
enough in distinguishing influenza from OFI. This is not
surprising as more than 60% of OFI cases included in
this series were individuals with pharyngitis or bronchitis
(Table 4), another viral infection commonly encountered
in the ER [38]. The information of this study are most
helpful for clinicians to facilitate diagnosis of influenza
during periods of high influenza activity in non-dengue
endemic setting.
In the present study, patients with influenza had a
shorter fever duration than the dengue cases (mean
2.8 ± 1.6 vs. 4.0 ± 2.3 days). This finding is similar to a
previous study that found a fever duration of <4 days for
patients with influenza [25], while the average length of
fever in dengue patients was approximately 5 days [39],
coinciding with the disappearance of viremia.
Although influenza primarily causes upper respiratory
tract infections, pulmonary and extra-pulmonary com-
plications have also been reported [2,40,41]. Previous
studies from the United States and Australia of critically
ill patients with 2009 pandemic H1N1 infections found
ARDS complication in 35.8% and 48.8% of cases and a
45% and 14.3% hospital mortality, respectively [40,41].
ARDS was noted in 5 influenza cases in our study
(Table 3); 3 were fatal. Remarkably, delayed oseltamivir
therapy was found in all fatal cases in our series. The
importance of a timely anti-viral therapy for severe influ-
enza should therefore be emphasized.
Earlier studies describe neurological complications of
influenza including aseptic meningitis, encephalopathy/
encephalitis, Guillain-Barré syndrome, and transverse
myelitis [42-44]. Neurological complications have been
reported for patients with 2009 pandemic H1N1 infec-
tions [43]. Of 447 patients with 2009 pandemic H1N1
infection in this study, meningoencephalitis was found
in 6 (1.3%), with presenting symptoms of altered mental
status and seizures (Table 3). Other influenza-associated
extrapulmonary complications among our patients in-
cluded myocarditis, rhabdomyolysis, gastrointestinal
bleeding, and intracranial hemorrhage (Table 3). Physicians
should be aware of influenza-associated extrapulmonary
complications when caring for influenza patients and man-
age them accordingly.
Gastrointestinal bleeding was the most common com-
plication among dengue patients in this study. Previous
studies have reported gastrointestinal bleeding to be a
warning sign of severe dengue; timely management and
intensive monitoring of patients with gastrointestinal
bleeding is therefore necessary [45].
This study has several limitations. First, because it was
conducted in a single medical center, disease severity
may have been biased by referral patterns. Second, as a
retrospective study, missing laboratory data was inevit-
able. Third, the decision to perform diagnostic tests for
influenza and dengue infections was based on individual
physicians’ experience; therefore, patients included in
our series may have been biased by individual physicians’
personal judgments. In addition, our results were based
on data from early stages of illness; future studies are ne-
cessary to validate these findings in different course of
illness for better generalization of their utility.
Conclusions
This study demonstrates substantial overlap in clinical
presentation between influenza and dengue as well as
OFI. This study also identifies simple and useful clinical
and laboratory data to enable identification and facili-
tate diagnosis of influenza in different clinical settings
(dengue and non-dengue endemic areas). We provide
two decision tree algorithms using simple clinical and
laboratory data that can be easily implemented in
resource-limited countries to differentiate patients with in-
fluenza from those with dengue. This information is espe-
cially important to clinicians in countries where medical
resources are sparse and the burden of influenza and den-
gue is high.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SYH and IKL made major contributions to sample collection and wrote the
manuscript. IKL conceived and designed the study, analysis of the data and
preparation of the manuscript. SYH, SCH, CCC, TYC, WCH, JWL and LW
collected clinical data. All authors read, commented on, and approved the
final manuscript.
Author details
1Department of Emergency Medicine, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung 833, Taiwan. 2Division of Infectious Diseases, Department
of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung
833, Taiwan. 3Department of Pediatrics, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung 833, Taiwan.
Received: 16 November 2013 Accepted: 7 November 2014
References
1. Briand S, Mounts A, Chamberland M: Challenges of global
surveillance during an influenza pandemic. Public Health 2011,
125(5):247–256.
Huang et al. BMC Infectious Diseases 2014, 14:623 Page 9 of 11
http://www.biomedcentral.com/1471-2334/14/623
2. Rothberg MB, Haessler SD, Brown RB: Complications of viral influenza.
Am J Med 2008, 121(4):258–264.
3. Murata Y, Walsh EE, Falsey AR: Pulmonary complications of interpandemic
influenza A in hospitalized adult. J Infect Dis 2007, 195(7):1029–1037.
4. Cate TR: Clinical manifestations and consequences of influenza. Am J Med
1987, 82(6A):15–19.
5. Guzmán MG, Kourí G: Dengue: an update. Lancet Infect Dis 2002,
2(1):33–42.
6. Tsai CY, Lee IK, Lee CH, Yang KD, Liu JW: Comparisons of dengue illness
classified based on the 1997 and 2009 World Health Organization
dengue classification schemes. J Microbiol Immunol Infect 2013,
46(4):271–281.
7. World Health Organization: Dengue Hemorrhagic Fever: Diagnosis, Treatment
and Control. Geneva: World Health Organization; 2009.
8. Silarug N, Foy HM, Kupradinon S, Rojanasuphot S, Nisalak A, Ponguswant Y:
Epidemic of fever of unknown origin in rural Thailand caused by
influenza A (H1N1) and dengue fever. Southeast Asian J Trop Med Public
Health 1990, 21(1):61–67.
9. Hussain R, Al-Omar I, Memish ZA: The diagnostic challenge of pandemic
H1N1 2009 virus in a dengue-endemic region: a case report of
combined infection in Jeddah, Kingdom of Saudi Arabia. J Infect
Public Health 2012, 5(2):199–202.
10. Lopez Rodriguez E, Tomashek KM, Gregory CJ, Munoz J, Hunsperger E,
Lorenzi OD, Irizarry JG, Garcia-Gubern C: Co-infection with dengue
virus and pandemic (H1N1) 2009 virus. Emerg Infect Dis 2010,
16(5):882–884.
11. Morens DM, Rigau-Pérez JG, López-Correa RH, Moore CG, Ruiz-Tibén EE,
Sather GE, Chiriboga J, Eliason DA, Casta-Velez A, Woodall JP: Dengue in
Puerto Rico, 1977: public health response to characterize and
control an epidemic of multiple serotypes. Am J Trop Med Hyg 1986,
35(1):197–211.
12. Lee IK, Lee WH, Yang KD, Liu JW: Comparison of the effects of oral
hydration and intravenous fluid replacement in adult patients with
non-shock dengue hemorrhagic fever in Taiwan. Trans R Soc Trop Med
Hyg 2010, 104(8):541–545.
13. Lee IK, Liu JW, Yang KD: Clinical and laboratory characteristics and risk
factors for fatality in elderly patients with dengue hemorrhagic fever.
Am J Trop Med Hyg 2008, 79(2):149–153.
14. Lee IK, Liu JW, Wang L, Yang KD, Li CC, Eng HL: 2009 pandemic influenza
A (H1N1): clinical and laboratory characteristics in pediatric and adult
patients and in patients with pulmonary involvement. Influenza Other
Respir Viruses 2012, 6(6):e152–161.
15. Cheng CK, Cowling BJ, Chan KH, Fang VJ, Seto WH, Yung R, Uyeki TM,
Houck PM, Peiris JS, Leung GM: Factors affecting QuickVue Influenza A + B
rapid test performance in the community setting. Diagn Microbiol Infect
Dis 2009, 65(1):35–41.
16. Shu PY, Huang JH: Current advances in dengue diagnosis. Clin Diagn Lab
Immunol 2004, 11(4):642–650.
17. World Health Organization: Clinical management of human infection with
pandemic (H1N1) 2009: revised guidance. Available at http://www.who.int/
csr/resources/publications/swineflu/clinical_management/en/index.html
(Accessed November 2009).
18. Trademarks: QIAGEN®: QIAamp Viral RNA Mini Kit-for purification of viral
RNA from cell-free body fluids. Available at http://www.qiagen.com/
MyQIAcube (Accessed November 2007).
19. World Health Organization: CDC protocol of real-time RT-PCR for influenza
A (H1N1). Geneva: World Health Organization.
20. Shu PY, Chang SF, Kuo YC, Yueh YY, Chien LJ, Sue CL, Lin TH, Huang JH:
Development of group- and serotype-specific one-step SYBR Green
I-based real-time reverse transcription-PCR assay for dengue virus. J Clin
Microbiol 2003, 41(6):2408–2416.
21. Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, Chien LJ, Chin C, Lin TH,
Huang JH: Comparison of capture immunoglobulin M (IgM) and IgG
enzyme-linked immunosorbent assay (ELISA) and nonstructural protein
NS1 serotype-specific IgG ELISA for differentiation of primary and
secondary dengue virus infections. Clin Diagnos Lab Immunol 2003,
10(4):622–630.
22. Shu PY, Yang CF, Kao JF, Su CL, Chang SF, Lin CC, Yang WC, Shih H,
Yang SY, Wu PF, Wu HS, Huang JH: Application of the dengue virus
NS1 antigen rapid test for onsite detection of imported dengue
cases at airports. Clin Vaccine Immunol 2009, 16(4):589e–91.
23. Centers for Disease Control, Department of Health, R.O.C (Taiwan): Guidelines
for dengue control. R.O.C (Taiwan): Centers for Disease Control, Department
of Health; 2009 [in Chinese].
24. Crichton NJ, Hinde JP, Marchini J: Models for diagnosing chest pain: is
CART helpful ? Stat Med 1997, 16(7):717–727.
25. Eccles R: Understanding the symptoms of the common cold and
influenza. Lancet Infect Dis 2005, 5(11):718–725.
26. Brydon EW, Morris SJ, Sweet C: Role of apoptosis and cytokines in
influenza virus morbidity. FEMS Microbiol Rev 2005, 29(4):837–850.
27. Matsukura S, Kokubu F, Kubo H, Tomita T, Tokunaga H, Kadokura M,
Yamamoto T, Kuroiwa Y, Ohno T, Suzaki H, Adachi M: Expression of
RANTES by normal airway epithelial cells after influenza virus A
infection. Am J Respir Cell Mol Biol 1998, 18(2):255–264.
28. Jeong I, Lee CH, Kim DK, Chung HS, Park SW: Mild form of 2009 H1N1
influenza infection detected by active surveillance: implications for
infection control. Am J Infect Control 2010, 38(6):482–485.
29. Higuera Iglesias AL, Kudo K, Manabe T, Corcho Berdugo AE, Corrales
Baeza A, Alfaro Ramos L, Guevara Gutiérrez R, Manjarrez Zavala ME,
Takasaki J, Izumi S, Bautista E, Perez Padilla JR: Reducing occurrence
and severity of pneumonia due to pandemic H1N1 2009 by early
oseltamivir administration: a retrospective study in Mexico. PLoS
One 2011, 6(7):e21838.
30. Simmons CP, Farrar JJ, Nguyen VV, Wills B: Dengue. N Engl J Med 2012,
366(15):1423–1432.
31. Hope-Simpson RE, Higgins PG: A respiratory virus study in Great Britain:
review and evaluation. Prog Med Virol 1969, 11:354–407.
32. Ryan-Poirier K: Influenza virus infection in children. Adv Pediatr Infect Dis
1995, 10:125–156.
33. Thomas EA, John M, Bhatia A: Cutaneous manifestations of dengue viral
infection in Punjab (north India). Int J Dermatol 2007, 46(7):715–719.
34. Saleem K, Shaikh I: Skin lesions in hospitalized cases of dengue Fever.
J Coll Physicians Surg Pak 2008, 18(10):608–611.
35. Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R,
Van Gompel A: Fever after a stay in the tropics: diagnostic
predictors of the leading tropical conditions. Medicine (Baltimore)
2007, 86(1):18–25.
36. Monmany J, Rabella N, Margall N, Domingo P, Gich I, Vazquez G:
Unmasking influenza virus infection in patients attended to in the
emergency department. Infection 2004, 32(2):89–97.
37. Writing Committee of the WHO Consultation on Clinical Aspects of
Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, Gao Z,
Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD,
Kumar A, Lim M, Shindo N, Penn C, Nicholson KG: Clinical aspects of
pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010,
362(18):1708–1719.
38. Kumar R, Tripathi P, Tripathi S, Kanodia A, Pant S, Venkatesh V: Prevalence
and clinical differentiation of dengue fever in children in northern India.
Infection 2008, 36(5):444–449.
39. Lee IK, Liu JW, Yang KD: Clinical characteristics and risk factors for
concurrent bacteremia in adults with dengue hemorrhagic fever. Am J
Trop Med Hyg 2005, 72(2):221–226.
40. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J,
Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S,
Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV,
Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L,
Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team:
Hospitalized patients with 2009 H1N1 influenza in the United States,
April-June 2009. N Engl J Med 2009, 361(20):1935–1944.
41. Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M,
Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C,
Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B,
Stephens D, Turner A, Yung M: Critical care services and 2009 H1N1
influenza in Australia and New Zealand. N Engl J Med 2009,
361(20):1925–1934.
42. Hjalmarsson A, Blomqvist P, Brytting M, Linde A, Skoldenberg B:
Encephalitis after influenza in sweden 1987-1998: a rare complication
of a common infection. Eur Neuro 2009, 61(5):289–294.
43. Glaser CA, Winter K, DuBray K, Harriman K, Uyeki TM, Sejvar J, Gilliam S,
Louie JK: A population-based study of neurologic manifestations of
severe influenza A (H1N1) pdm09 in california. Clin Infect Dis 2012,
55(4):514–520.
Huang et al. BMC Infectious Diseases 2014, 14:623 Page 10 of 11
http://www.biomedcentral.com/1471-2334/14/623
44. Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V,
Rozenberg F, Caudie C, Annane D, van der Werf S, Lebon P, Raphaël JC,
Gaillard JL, Gault E: Guillain-barre syndrome and influenza virus infection.
Clin Infect Dis 2009, 48(1):48–56.
45. Lee IK, Liu JW, Yang KD: Fatal dengue hemorrhagic fever in adults:
emphasizing the evolutionary pre-fatal clinical and laboratory
manifestations. PLoS Negl Trop Dis 2012, 6(2):e1532.
doi:10.1186/s12879-014-0623-z
Cite this article as: Huang et al.: Use of simple clinical and laboratory
predictors to differentiate influenza from dengue and other febrile
illnesses in the emergency room. BMC Infectious Diseases 2014 14:623.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huang et al. BMC Infectious Diseases 2014, 14:623 Page 11 of 11
http://www.biomedcentral.com/1471-2334/14/623
